Atyr Pharma, Stock Fundamentals
| ATYR Stock | 3.44 0.15 4.56% |
aTyr Pharma, fundamentals help investors to digest information that contributes to ATyr Pharma,'s financial success or failures. It also enables traders to predict the movement of ATyr Stock. The fundamental analysis module provides a way to measure ATyr Pharma,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ATyr Pharma, stock.
At this time, ATyr Pharma,'s Cost Of Revenue is relatively stable compared to the past year. As of 11/28/2024, Total Other Income Expense Net is likely to grow to about 4.7 M, while Depreciation And Amortization is likely to drop slightly above 1.9 M. ATyr | Select Account or Indicator |
aTyr Pharma, Company Shares Outstanding Analysis
ATyr Pharma,'s Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current ATyr Pharma, Shares Outstanding | 75.8 M |
Most of ATyr Pharma,'s fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, aTyr Pharma, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ATyr Shares Outstanding Historical Pattern
Today, most investors in ATyr Pharma, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ATyr Pharma,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ATyr Pharma, shares outstanding as a starting point in their analysis.
ATyr Pharma, Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
ATyr Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, aTyr Pharma, has 75.8 M of shares currently outstending. This is 58.02% lower than that of the Biotechnology sector and 29.07% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 86.74% higher than that of the company.
aTyr Pharma, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ATyr Pharma,'s current stock value. Our valuation model uses many indicators to compare ATyr Pharma, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ATyr Pharma, competition to find correlations between indicators driving ATyr Pharma,'s intrinsic value. More Info.aTyr Pharma, is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, ATyr Pharma,'s Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ATyr Pharma, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ATyr Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ATyr Pharma,'s direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ATyr Pharma, could also be used in its relative valuation, which is a method of valuing ATyr Pharma, by comparing valuation metrics of similar companies.ATyr Pharma, is currently under evaluation in shares outstanding category among its peers.
ATyr Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (106.33) % | ||||
| Current Valuation | 79.38 M | ||||
| Shares Outstanding | 75.8 M | ||||
| Shares Owned By Insiders | 2.39 % | ||||
| Shares Owned By Institutions | 64.48 % | ||||
| Number Of Shares Shorted | 2.11 M | ||||
| Price To Book | 1.76 X | ||||
| Price To Sales | 244.92 X | ||||
| Revenue | 353 K | ||||
| EBITDA | (52.18 M) | ||||
| Net Income | (50.39 M) | ||||
| Total Debt | 15.1 M | ||||
| Book Value Per Share | 1.08 X | ||||
| Cash Flow From Operations | (33.22 M) | ||||
| Short Ratio | 1.47 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Target Price | 22.0 | ||||
| Number Of Employees | 56 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 144.01 M | ||||
| Total Asset | 120.65 M | ||||
| Retained Earnings | (468.02 M) | ||||
| Working Capital | 86.58 M | ||||
| Net Asset | 120.65 M |
About ATyr Pharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze aTyr Pharma,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATyr Pharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of aTyr Pharma, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 0.90 | 0.80 | |
| Total Revenue | 353 K | 335.4 K | |
| Cost Of Revenue | 2.7 M | 4.6 M | |
| Stock Based Compensation To Revenue | 7.37 | 7.73 | |
| Sales General And Administrative To Revenue | 36.77 | 38.61 | |
| Research And Ddevelopement To Revenue | 119.81 | 125.80 | |
| Capex To Revenue | 11.94 | 12.54 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (155.58) | (147.80) |
Pair Trading with ATyr Pharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ATyr Pharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma, will appreciate offsetting losses from the drop in the long position's value.Moving together with ATyr Stock
| 0.78 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against ATyr Stock
| 0.87 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.78 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.77 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.74 | PEPG | PepGen | PairCorr |
| 0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to ATyr Pharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma, to buy it.
The correlation of ATyr Pharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ATyr Pharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ATyr Stock Analysis
When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.